111 Capital Gilead Sciences, Inc. Transaction History
111 Capital
- $582 Billion
- Q2 2025
A detailed history of 111 Capital transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, 111 Capital holds 22,908 shares of GILD stock, worth $2.76 Million. This represents 0.44% of its overall portfolio holdings.
Number of Shares
22,908
Previous 32,587
29.7%
Holding current value
$2.76 Million
Previous $3.65 Billion
30.44%
% of portfolio
0.44%
Previous 0.7%
Shares
3 transactions
Others Institutions Holding GILD
# of Institutions
2,297Shares Held
1BCall Options Held
9.46MPut Options Held
9.94M-
Black Rock Inc. New York, NY121MShares$14.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.4 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.5MShares$7.17 Billion0.28% of portfolio
-
Capital Research Global Investors Los Angeles, CA54.6MShares$6.58 Billion1.39% of portfolio
-
Capital World Investors Los Angeles, CA53.5MShares$6.45 Billion1.01% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $151B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...